Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan C Lynch

Showing results (1-10 of 76) with videos related to

Pageof 8
Sort By:
Blood|February 29, 2024
Toward a cure for cHL without chemotherapyRyan C Lynch
Expert Opinion on Pharmacotherapy|September 15, 2015
Chemotherapy options for previously untreated acute myeloid leukemiaRyan C Lynch, Bruno C Medeiros
British Journal of Haematology|May 3, 2024
Managing common toxicities associated with checkpoint inhibitor and chemotherapy combinations for untreated classic Hodgkin lymphomaThomas M Kuczmarski, Ryan C Lynch
Seminars in Radiation Oncology|December 13, 2024
Rising to the Top: How Immune-Checkpoint Inhibitors are Changing the Landscape of Treatment for Classic Hodgkin LymphomaRyan C Lynch, Michael Sargent Binkley
Blood Advances|December 9, 2025
Pharma steps back from Hodgkin lymphoma: now what?Ryan C Lynch, Ajay K Gopal
Hemasphere|May 13, 2025
Optimizing therapy for relapsed/refractory classic Hodgkin lymphoma in the era of PD-1 blockadeThomas M Kuczmarski, Ryan C Lynch
Hematology. American Society of Hematology. Education Program|December 7, 2024
Has PD-1 blockade changed the standard of care for cHL?Thomas M Kuczmarski, Ryan C Lynch
Hematology/Oncology Clinics of North America|June 27, 2020
Phosphatidylinositol-3-Kinase Inhibition in Follicular LymphomaRyan C Lynch, Ajay K Gopal
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 2, 2016
Risk-Adapted Treatment of Advanced Hodgkin Lymphoma With PET-CTRyan C Lynch, Ranjana H Advani
Cancer|April 13, 2018
Have we found the right patient population for transplantation in follicular lymphoma?Ryan C Lynch, Ajay K Gopal
Pageof 8

Showing results (1-10 of 76) with videos related to

Sort By:
Pageof 8
Blood|February 29, 2024
Toward a cure for cHL without chemotherapyRyan C Lynch
Expert Opinion on Pharmacotherapy|September 15, 2015
Chemotherapy options for previously untreated acute myeloid leukemiaRyan C Lynch, Bruno C Medeiros
British Journal of Haematology|May 3, 2024
Managing common toxicities associated with checkpoint inhibitor and chemotherapy combinations for untreated classic Hodgkin lymphomaThomas M Kuczmarski, Ryan C Lynch
Seminars in Radiation Oncology|December 13, 2024
Rising to the Top: How Immune-Checkpoint Inhibitors are Changing the Landscape of Treatment for Classic Hodgkin LymphomaRyan C Lynch, Michael Sargent Binkley
Blood Advances|December 9, 2025
Pharma steps back from Hodgkin lymphoma: now what?Ryan C Lynch, Ajay K Gopal
Hemasphere|May 13, 2025
Optimizing therapy for relapsed/refractory classic Hodgkin lymphoma in the era of PD-1 blockadeThomas M Kuczmarski, Ryan C Lynch
Hematology. American Society of Hematology. Education Program|December 7, 2024
Has PD-1 blockade changed the standard of care for cHL?Thomas M Kuczmarski, Ryan C Lynch
Hematology/Oncology Clinics of North America|June 27, 2020
Phosphatidylinositol-3-Kinase Inhibition in Follicular LymphomaRyan C Lynch, Ajay K Gopal
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 2, 2016
Risk-Adapted Treatment of Advanced Hodgkin Lymphoma With PET-CTRyan C Lynch, Ranjana H Advani
Cancer|April 13, 2018
Have we found the right patient population for transplantation in follicular lymphoma?Ryan C Lynch, Ajay K Gopal
Pageof 8